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IntroductIon 
Secondary hyperparathyroidism (sHPT) develops progres-
sively during the course of chronic kidney disease (CKD). 
Hypocalcemia, phosphate  retention and  the related deficit 
in 1,25-dihydroxycholecalciferol (1,25(OH)2D3) stimulate the 
synthesis and release of  parathyroid hormone (PTH) and 
fibroblast growth factor-23 (FGF-23) (1, 2). The enduring al-
terations of mineral metabolism caused by uremia and pro-
gressive loss of nephron mass are responsible of continu-
ous stimulation of parathyroid cells. Cells biology changes 
so it induces cell hypertrophy-hyperplasia and the selection 
of cell clones with reduced calcium receptor (CaR) and vita-
min D receptor (VDR) density (1). 
Glandular hyperplasia is at first polyclonal and widespread 
then monoclonal and nodular. In severe sHPT, parathyroid 
glands become less responsive to hormonal stimuli. This 
may trigger a disorder of cellular growth which can lead to 
tertiary or autonomous hyperparathyroidism (3, 4). Nodu-
lar hyperplasia does not involve all parathyroid glands, nor 
does it affect all patients with CKD equally; therefore, it can 
be assumed that genetic mechanisms are involved in its 
development, although the exact mechanisms are currently 
unknown (3, 5-7).
Nowadays, sHPT diagnosis is based on biochemical pa-
rameters of mineral metabolism because the identifica-
tion of normal parathyroid glands is difficult with all imag-
ing techniques. However, high-resolution sonography with 
color Doppler (US/CD), performed by skilled operators, can 
localize hyperplastic parathyroid glands. Indeed, hyperplas-
tic glands become hypoechoic and well distinguished from 
the thyroid parenchyma due to their increased cellularity 
and reduction of adipose stromal tissue. US/CD is the only 
technique that measures volumetric variations of parathy-
roid glands, simultaneously providing semiquantitative pa-
rameters for glandular perfusion during the progression of 
sHPT (8, 9).
AbstrAct 
Secondary hyperparathyroidism (sHPT) is one of the 
most common and serious complications of chronic 
kidney disease (CKD) and maintenance hemodialysis 
(MHD). In sHPT, the biology of parathyroid cells chang-
es significantly toward diffuse and nodular hyperpla-
sia. Diagnosis and treatment of sHPT are based on in-
tact parathyroid hormone (i-PTH) serum levels and on 
the parameters of mineral metabolism. The morpho-
logical diagnosis of sHPT relies on 2 complementary 
imaging techniques: high-resolution ultrasonography 
with color Doppler imaging (US/CD) and 99mTc-me-
thoxyisobutylisonitrile (MIBI) scintigraphy. 
The main objective of this review is to stimulate ne-
phrologists to use US/CD of the parathyroid glands 
during the progression of CKD in order to aid clinical, 
pharmacological and surgical strategies. The primary 
role of US/CD in sHPT should be to integrate the clini-
cal diagnosis by defining the number and volume of 
hyperplastic glands, although the international guide-
lines do not state when and why to perform US/CD. 
This review also evaluates the role of US/CD in clinical 
follow-up and assessment of therapeutic response of 
sHPT, and it highlights how US/CD can evaluate the ef-
fect of therapy with phosphate binders, vitamin D or its 
analogues and  calcimimetics, which are changing the 
natural history of sHPT and  the frequency of parathy-
roidectomy. Evaluation of the morphological and vas-
cular changes of hyperplastic parathyroids is useful to 
guide percutaneous ethanol injection therapy and to 
support clinical, pharmacological and surgical strate-
gies. Epidemiological studies are needed to establish 
how US/CD could change the management of sHPT 
and why it should be repeated in patients with high 
levels of serum  i-PTH.
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Methods, equIpMent And pArAMeters to 
be consIdered when perforMIng us/cd
Anatomical characteristics of parathyroid glands are summa-
rized in Table I. Standard procedure for  examination of the 
cervical region requires that patients are in a supine position, 
with their neck hyperextended and slightly deviated, first to 
the right and then to the left, to allow exploration of the lat-
erocervical region, from the corner of the jaw to the superior 
mediastinum. High-resolution linear probes (7.5-14 MHz), 
extended field of view and compound harmonic imaging 
should be used to improve spatial resolution and B-mode 
image quality. CD sampling of glandular flow should be ob-
tained with a transmission frequency of 3.8 MHz, a pulse 
repetition frequency <800 kHz and a medium-high color gain 
(i.e., 45-50 on a scale of 0-60) (12). 
Normal parathyroid glands, which are rich in adipose cells, 
appear structurally similar to the thyroid parenchyma, mak-
ing them difficult to distinguish even using high-resolution 
probes (10, 11, 13). Primary or secondary cellular hyperpla-
sia, however, makes the glands diffusely hypoechoic com-
pared with the thyroid parenchyma, and well outlined by a 
thin hyperechoic edge. There is no defined size limit over 
which a parathyroid gland can be considered pathological, 
although a hypoechoic gland, well distinguished from the 
thyroid parenchyma and with 2 diameters >5 mm, is gener-
ally considered to be hyperplastic (14) (Fig. 1).
The major limit of US/CD is the operator-dependence where-
as safety, repeatability, lower cost and the ability to assess 
the changes in glandular volume give US/CD a unique ad-
TABLE I  
ANATOMICAL CHARACTERISTICS OF PARATHYROID 
GLANDS (10, 11)
Number •   Four glands (2 superior, 2 inferior). 
They are small (20-40 mg) and have a 
bean-like shape
Development •   Superior glands arise from the 4th 
pharingeal pouch (PIV)
•   Inferior glands arise from the 3rd phar-
ingeal pouch (PIII) 
Location •   PIV - Posterolateral profile of superior 
thyroid pole (at the cricothyroidal carti-
lage junction, 1 cm above the intersec-
tion of the inferior thyroid artery and 
the recurrent laryngeal nerve)
•   PIII - More variable (near the lower 
pole of the thyroid or between the 
thyroid pole and the thymus horn)  
Vascular 
anatomy
•   PIV and PIII are supplied by the inferior 
thyroid artery of thyreocervical trunk
Anatomical 
anomalies
•   Absence of 1 parathyroid (i.e., <4 
glands): 3% of cases
•   Accessory or supernumerary: 13% of 
cases
•   Ectopic glands: 15%-29% of cases 
Fig. 1 - Parathyroid hyperplasia. 
a) Transversal plane on right thy-
roid lobe. b) Longitudinal plane 
and c) transversal plane on left 
thyroid lobe. Hyperplastic para-
thyroids (white arrows) appear 
as a clearly edged hypoechoic 
nodule, with a thin hyperechoic 
capsule. Gland diameters are 
5-6 mm. d-f) Longitudinal scan 
on thyroid lodge. Nodular hyper-
plasia appears as a hypoechoic 
nodule (white arrows) with a thin 
hyperechoic capsule, a long-
axis diameter >1 cm and a vol-
ume >500 mm3, behind the thy-
roid lobe. Histological analysis 
suggests that glands <500 mm3 
show diffuse or multinodular 
polyclonal hyperplasia, whereas 
glands >500 mm3 present mono-
clonal nodular hyperplasia in 
80% of cases. T = thyroid; V = 
cervical vertebra.
This review highlights the pivotal role of US/CD in diagnosis, 
clinical follow-up, therapeutic response to drugs, percutaneous 
alcoholization and presurgical assessment of sHPT.  
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vantage over other imaging techniques (e.g., single-photon 
emission computed tomography [SPECT]-scintigraphy, 
computed tomography [CT] and magnetic resonance [MR]). 
Glandular volume (in cubic millimeters) is calculated using 
the formula of an irregular ellipsoid (4/3 π × ½ anteroposte-
rior diameter × ½ laterolateral diameter × ½ craniocaudal 
diameter). The increase in glandular volume should mean an 
increased PTH secretion and a worsening of sHPT (1, 15). 
Indeed, there is a weak linear relationship between glandu-
lar volume and serum levels of intact parathyroid hormone 
(i-PTH) (16). The correlation between glandular volume and 
histological features demonstrates that glands <500 mm3 
show diffuse or multinodular and polyclonal hyperplasia, 
whereas glands >500 mm3 are affected by monoclonal nod-
ular hyperplasia in 80% of cases (17). 
Both in primary hyperparathyroidism and in sHPT, the in-
crease in volume of parathyroid glands is associated with 
a widespread increase in vascularity, evident at histology 
and at US/CD sampling (18-22) (Fig. 2). Usually, in CD, we 
can distinguish 3 different patterns: (i) glands with no Dop-
pler signal; (ii) hypovascularized glands with a poor or weak 
Doppler signal, represented by occasional color spots in the 
hilar/endonodular region; and (iii) hypervascularized glands, 
with an enlarged feeding artery at the hilum, a peripheral 
arc of vascularity and/or ray-like endonodular vessels. Oc-
casionally, it is possible to record a spectral signal at the 
hilum; in these cases, the peak systolic velocity is about 
15-30 cm/s (11, 19). Sonographic characteristics of parathy-
roid glands are summarized in Table II. 
There is no evidence that suggests any correlation between 
vascular pattern and glandular function (20-23). A hyper-
Fig. 2 - Vascular pattern of hy-
perplastic parathyroids. High-
resolution ultrasonography with 
color Doppler imaging (US/CD) 
sampling can demonstrate 3 
different vascular patterns: (i) 
glands without vascularization; 
(ii) hypovascularized glands with 
a poor or weak Doppler shift (oc-
casional color spots in the hilar/
endonodular region) (a-c); (iii) 
hypervascularized glands (en-
larged feeding artery at the hi-
lum, peripheral arc of vascular-
ity and/or ray-like endonodular 
vessels) (d-f). Asterisk indicates 
transversal process of cervical 
vertebra; arrowhead points to 
colloidal nodule of thyroid gland. 
T = thyroid; V = cervical vertebra.
TABLE II 
SONOGRAPHIC CHARACTERISTICS OF PARATHYROID 
GLANDS (11, 13-19)
Definition of  
hyperplasia at US
•  Two diameters >5 mm
Gray-scale pattern •  Normal glands: indistinguishable 
from thyroid parenchyma
•  Hyperplastic glands: hypoe-
choic, volume <500 mm3
•  Nodular glands: hypoechoic. 
Rare cysts or calcifications. 
Volume >500 mm3
Vascular pattern  
at US/CD
• Glands without vascularization
•  Hypovascularized glands with a 
poor or weak Doppler shift (oc-
casional color spots in the hilar/
endonodular region)
•  Hypervascularized glands 
(enlarged feeding artery at the 
hilum, peripheral arc of vascula-
rity and/or ray-like endonodular 
vessels)
Histology of  
excised glands
•  Volume <500 mm3: usually 
hyperplastic glands 
•  Volume >500 mm3: nodular 
hyperplasia in 80% of cases
CD = color Doppler imaging; US = ultrasonography.
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functioning gland >500 mm3 is hypervascularized but may 
be hypovascularized or avascularized due to inadequate 
sampling, artefacts, deep localization in the neck or medi-
astinum and cinacalcet therapy.
hIgh-resolutIon ultrAsound 
And dIAgnosIs of secondAry  
hyperpArAthyroIdIsM
Diagnosis and treatment of sHPT are based on serum i-PTH 
levels and on the parameters of mineral metabolism, though 
the determination of PTH can pose some problems because 
of the heterogeneity of the molecule and the important bio-
logical, preanalytical and postanalytical variability (23). 
Although i-PTH and biochemical data are pivotal in defining 
clinical aspects of sHPT, they do not give information about 
the morphology and volume of the gland(s).The primary role 
of US/CD in sHPT should be to integrate the clinical diag-
nosis by defining the number and volume of hyperplastic 
glands, although the international guidelines do not state 
when and why to perform US/CD. Our policy is to perform 
a US/CD scan when serum i-PTH levels are >400 pg/mL for 
at last 3 determinations in 3 months in dialysis or predialysis 
patients. In clinical practice, it is not uncommon to find that 
patients with CKD stage 5 have i-PTH >400 pg/mL but no 
hyperplastic glands at US/CD. In these cases, the mismatch 
between morphological and biochemical data may be due 
to (i) the inadequacy of therapy, (ii) the lack of therapeutic 
compliance, (iii) a false US/CD negative or (iv) an analytical 
mistake in evaluating serum i-PTH levels. In these cases, 
if the increase in serum i-PTH levels is confirmed by fur-
ther dosages, the regimen has been checked and the 
patient’s compliance has been reinforced, then SESTAMIBI- 
scintigraphy or hybrid techniques such as SPECT-CT should 
be performed to exclude the presence of ectopic glands 
undetectable with US/CD for their location. Nevertheless, 
scintigraphy is more invasive, expensive and time-consum-
ing, and its sensitivity and specificity in sHPT are lower than 
those of US/CD (17, 19, 24). Therefore, US/CD must be con-
sidered the first-line imaging diagnostic tool in the clinical 
diagnosis of sHPT, whereas scintigraphy has a complemen-
tary role. US/CD should be repeated once a year in patients 
receiving conservative or dialytic therapy with high levels of 
serum i-PTH in order to evaluate an initial or nodular hyper-
plasia. The best solution would be to have the expertise in 
an ultrasound section in the nephrology unit in order to be 
directly involved in the diagnosis, clinical follow-up and treat-
ment of their own patients.
AssessMent of the progressIon of  
secondAry hyperpArAthyroIdIsM
Serum i-PTH changes do not provide an accurate evaluation 
of severity of sHPT. In fact, serum i-PTH does not correlate 
with glandular masses in patients treated with phosphate 
binders, vitamin D or analogues and cinacalcet − while mor-
phofunctional parameters (volume and perfusional pattern) 
show a progression related to the duration and severity of 
the uremic state (15, 16).
Parameters to be considered for the assessment of sHPT 
progression include (i) the echogenicity of the gland (Fig. 3a); 
(ii) gland diameter (25, 26) and volume (19); (iii) the appear-
ance of involutive cystic phenomena as anechoic areas with 
no vascularization; and (iv) the evidence of fibrocalcifications 
(Fig. 3b) (22). Gray-scale parameters must be completed with 
CD sampling to characterize the vascular pattern. Changes in 
morphological and perfusional patterns are indicative of the 
functional state of the gland. Consequently, the morphological 
changes followed by serial controls can evaluate the progres-
sion of sHPT and efficacy of the pharmacological treatment.
Fig. 3 - Gray-scale parameters 
of secondary hyperparathyroid-
ism progression. a, b) After long-
term treatment with conventional 
therapy and cinacalcet, parathy-
roid gland can show involutive 
phenomena such as hyperecho-
genicity (arrowhead), cystic le-
sions (asterisk) or calcifications 
(white arrows). T = thyroid lobe. 
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us/cd to defIne surgIcAl tIMIng of 
shpt
Presurgical imaging in sHPT is less important than in pri-
mary hyperparathyroidism. In fact, in sHPT, hyperplasia 
does not involve equally all parathyroid glands, so in any 
case to excise the hyperplastic glands, it is mandatory to 
perform a conventional explorative cervicotomy. Converse-
ly, in primary hyperparathyroidism, the first choice surgical 
technique is the videoscopic parathyroidectomy, in which it 
is pivotal to know the exact location of the adenoma to re-
duce surgical time and associated risks (27-30). As in sHPT 
there is a wide variation in glandular volume, the overall 
sensitivity of US/CD is lower than in primary hyperpara-
thyroidism and does not exceed 74%-75% (<50% in the 
localization of parathyroids <500 mm3, >90% in glands 
≥500 mm3) (17, 19). Based on these observations, the role 
of US/CD should not therefore be to localize the glands 
but instead to define the surgical timing. In fact, accord-
ing to Kidney Disease Improving Global Outcomes (KDIGO) 
guidelines, parathyroidectomy is indicated in patients with 
CKD stages 3-5D when serum i-PTH, Ca, P and Ca x P 
product are no longer controlled by conventional therapy 
(31), but also when US/CD shows 1 or more nodular hyper-
plastic parathyroids ≥500 mm3 (32, 33). 
ultrAsound-guIded pArAthyroId glAnd 
AlcoholIzAtIon
Ultrasound percutaneous ethanol injection therapy (PEIT) 
is an interventional procedure used in advanced sHPT to 
induce chemical ablation of the parathyroid glands larger 
than 1 cm in diameter or 0.5 cm3 in calculated volume (34). 
The interval between initial and subsequent additional eth-
anol injections varies depending upon the protocol. Glands 
are selectively destroyed by injection of 90% ethanol with 
1% lidocaine under US/CD guidance. For safety, the initial 
injection volume should not exceed 80% of the calculated 
volume of the gland. Gray-scale US is used to confirm that 
the needle tip is in the center of the gland, whereas CD is 
used to establish the residual blood supply and the need 
for additional ethanol injections (34).  To date, no serious 
adverse effects related with this practice have been report-
ed (35), whereas several reports suggest a significant re-
duction of i-PTH in up to 89% of cases. Efficacy of PEIT in 
maintenance hemodialysis (MHD) patients with sHPT is re-
lated to the number of hyperplastic parathyroid glands. The 
best results in terms of efficacy rate, remission period and 
risk of relapse are obtained when the treatment is limited to 
patients with only 1 hyperplastic gland >0.5 cm (36). How-
ever, while the short-term results of PEIT are promising, the 
longer-term ones remain controversial because they are 
not comparable with parathyroidectomy. Nowadays, the 
only indication to PEIT is recurrent sHPT untreatable with 
parathyroidectomy. Percutaneous injection of calcitriol has 
also been proposed to reduce glandular mass via hyper-
stimulation of VDRs (37), however this method has yielded 
poor results to date (38). 
MorphologIcAl chAnges of pArAthyroId 
glAnds: AssessIng effIcAcy of conven-
tIonAl therApy And cAlcIMIMetIcs
Glandular volume is directly related to the number and vol-
ume of glands detected, but in severe sHPT, it is variable 
and not always correlated with serum i-PTH levels (15). 
This observation suggests that the biggest glands tend 
to disengage from receptor control mechanisms (i.e., the 
up-regulation of CaR and VDR) and grow independently. 
The release of  PTH in this condition is not proportional to 
total glandular volume. The combination of conventional 
therapy  (phosphate binders, vitamin D or analogues) with 
cinacalcet marks a clear reversal in the progression of the 
disease: serum PTH levels are reduced, mineral metabolism 
is stabilized, US/CD analysis reveals progressive changes in 
Fig. 4 - Morphological changes of 
parathyroid glands after cinacal-
cet. Before cinacalcet, the gland 
was hypoechoic with a solid ap-
pearance. a-c) After 18 months 
of cinacalcet and conventional 
therapy, the gland’s volume was 
reduced and areas of cystic de-
generation appeared (asterisk). A 
diffuse hypovascularization was 
evident. Cc = common carotid 
artery.
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cases, there was an evident mismatch: 19.3% of patients 
with i-PTH ≤400 pg/mL had glandular hyperplasia, whereas 
48.5% of patients with i-PTH >400 pg/mL did not present 
hyperplasia. In these subgroups of patients, serum i-PTH 
levels were unable to define the grading of sHPT. In con-
trast, by comparing i-PTH values to US/CD features we have 
been able to distinguish those cases in which the treatment 
is adequate  despite  the glandular hyperplasia, from those 
in which i-PTH is high due an inadequate pharmacological 
treatment or lack of compliance. Considering the feasibility 
and repeatability of US/CD, an yearly exam would be useful 
to image an initial or nodular hyperplasia, to evaluate the 
progression of hyperplasia and to aid clinical, pharmaco-
logical and surgical strategies.
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volume and vascularization is reduced after 12-18 months 
(13, 39). The regression of hyperplasia is like a “chemical 
parathyroidectomy,” which is associated with a satisfac-
tory control of mineral metabolism and delays the need 
for surgery (40). In the biggest glands (≥500 mm3), volume 
reduction (>60%) is associated with a loss of vascular 
signal, progressing to complete disappearance of vascu-
larization. The majority of glands develop involutive phe-
nomena (cystic-like lesions), whereas in glands with volume 
<500 mm3, the volume reduction is accompanied by a 
structural change toward hyperechogenicity, as if the rela-
tionship between cellularity and stromal adipose tissue had 
been reversed (Fig. 4) (41). This suggests that calcimimetic 
treatment is able to modulate the biological response of the 
cell with uncontrolled proliferation via a direct stimulation 
of the CaR and VDR expression (42). The synergic action 
of calcimimetic and vitamin D with phosphate binders on 
physiological receptor stimulation could explain the regres-
sion of morphological sHPT. It has yet to be determined 
whether this regression occurs because of an increase in 
cell apoptosis, as suggested by some experimental studies 
(43, 44), or because of the direct action of the calcimimetic 
on vessels or adipocytes.
future dIrectIons 
Epidemiological studies are needed to establish how 
US/CD could change the management of sHPT and why 
it should be repeated in patients with high levels of serum 
i-PTH. In our series of 395 consecutive CKD stage 5D pa-
tients, a concordance between i-PTH levels and US/CD 
features was evident in 73.4%. Vice versa, in 26.6% of 
references
1. Drüeke TB. Cell biology of parathyroid gland hyperplasia in 
chronic renal failure. J Am Soc Nephrol. 2000;11(6):1141-1152.
2. Wetmore JB, Quarles LD. Calcimimetics or vitamin D ana-
logs for suppressing parathyroid hormone in end-stage renal 
disease: time for a paradigm shift? Nat Clin Pract Nephrol. 
2009;5(1):24-33. 
3. Parfitt AM. The hyperparathyroidism of chronic renal failure: 
a disorder of growth. Kidney Int. 1997;52(1):3-9. 
4. Fukagawa M. Cell biology of parathyroid hyperplasia in ure-
mia. Am J Med Sci. 1999;317(6):377-382. 
5. Arnold A, Brown MF, Ureña P, Gaz RD, Sarfati E, Drüeke 
TB. Monoclonality of parathyroid tumors in chronic renal 
failure and in primary parathyroid hyperplasia. J Clin Invest. 
1995;95(5):2047-2053. 
6. Salem MM. Hyperparathyroidism in the hemodialysis popula-
tion: a survey of 612 patients. Am J Kidney Dis. 1997;29(6): 
862-865. 
7. Afonso S, Santamaría I, Guinsburg ME, et al. Chromosomal 
aberrations, the consequence of refractory hyperparathy-
7© 2012 Società Italiana di Nefrologia - ISSN 1121-8428  
JN (0000; :00) 000-00000EPHROL
roidism: its relationship with biochemical parameters. Kidney 
Int Suppl. 2003;85(85):S32-S38. 
8. Fukagawa M, Kitaoka M, Yi H, et al. Serial evaluation of para-
thyroid size by ultrasonography is another useful marker for 
the long-term prognosis of calcitriol pulse therapy in chronic 
dialysis patients. Nephron. 1994;68(2):221-228. 
9. Katoh N, Nakayama M, Shigematsu T, et al. Presence of 
sonographically detectable parathyroid gland can predict 
resistance to oral pulsed-dose calcitriol treatment of sec-
ondary hyperparathyroidism. Am J Kidney Dis. 2000;35(3): 
465-468. 
10. Bannister LH, Berry MM, Collins P, et al. eds. Gray’s 
anatomy. New York, NY: Churchill Livingstone; 1995:17.
11. Steward DL, Hainston JA. Development and surgical anat-
omy of the thyroid compartment. In: Terris DJ, Gourin CG, 
eds. Thyroid and parathyroid diseases. New York, NY: 
Thieme; 2009:11-17.
12. Solbiati L, Charboneau JW, Osti W, et al. The thyroid gland. 
In: Rumack CM, Wilson SR, Charboneau JW, eds. Diagnostic 
ultrasound. 3rd ed. Chap. 21. St Louis, MO: Elsevier Mosby; 
2005:735-770.
13. Meola M, Petrucci I, Barsotti G. Long-term treatment with 
cinacalcet and conventional therapy reduces parathyroid hy-
perplasia in severe secondary hyperparathyroidism. Nephrol 
Dial Transplant. 2009;24(3):982-989. 
14. Pavlovic D. Prevention and treatment of secondary hy-
perparathyroidism: still a challenge for the nephrologist? 
Nephrol Dial Transplant. 2003;18(90005):S45-S46. 
15. Indridason OS, Heath H III, Khosla S, Yohay DA, Quarles LD. 
Non-suppressible parathyroid hormone secretion is related to 
gland size in uremic secondary hyperparathyroidism. Kidney 
Int. 1996;50(5):1663-1671. 
16. Matsuoka S, Tominaga Y, Sato T, et al. Relationship be-
tween the dimension of parathyroid glands estimated 
by ultrasonography and the hyperplastic pattern in pa-
tients with renal hyperparathyroidism. Ther Apher Dial. 
2008;12(5):391-395. 
17. Périé S, Fessi H, Tassart M, et al. Usefulness of combination 
of high-resolution ultrasonography and dual-phase dual-iso-
tope iodine 123/technetium Tc 99m sestamibi scintigraphy 
for the preoperative localization of hyperplastic parathy-
roid glands in renal hyperparathyroidism. Am J Kidney Dis. 
2005;45(2):344-352. 
18. Martins P, Schmitt F, Almeida H, Frazão JM. Evaluation of 
parathyroid gland angiogenesis in chronic kidney disease 
associated with secondary hyperparathyroidism. Nephrol 
Dial Transplant. 2008;23(9):2889-2894. 
19. Meola M, Petrucci I, Calliada F, et al. Presurgical setting 
of secondary hyperparathyroidism using high-resolution 
sonography and color Doppler. Ultraschall Med. 2011;32 
(S 01)(Suppl 1):S74-S82. 
20. Calliada F, Sala G, Conti MP, et al. [Clinical applications of 
color-Doppler: the parathyroid glands.] Article in Italian. Ra-
diol Med. 1993;85(5 Suppl 1):114-9. 
21. Lane MJ, Desser TS, Weigel RJ, Jeffrey RB Jr. Use of color 
and power Doppler sonography to identify feeding arteries 
associated with parathyroid adenomas. AJR Am J Roentgenol. 
1998;171(3):819-823.
22. Gooding GAW, Clark OH. Use of color Doppler imaging in 
the distinction between thyroid and parathyroid lesions. Am 
J Surg. 1992;164(1):51-56. 
23. Souberbielle JC, Boutten A, Carlier M-C, et al. Inter-method 
variability in PTH measurement: implication for the care of 
CKD patients. Kidney Int. 2006;70(2):345-350. 
24. Taillefer R, Boucher Y, Potvin C, Lambert R. Detection and 
localization of parathyroid adenomas in patients with hyper-
parathyroidism using a single radionuclide imaging proce-
dure with technetium-99m-sestamibi (double-phase study). 
J Nucl Med. 1992;33(10):1801-1807.
25. Vulpio C, Bossola M, De Gaetano A, et al. Ultrasound patterns 
of parathyroid glands in chronic hemodialysis patients with 
secondary hyperparathyroidism. Am J Nephrol. 2008;28(4): 
589-597. 
26. Matsuoka S, Tominaga Y, Sato T, et al. Relationship between 
the dimension of parathyroid glands estimated by ultraso-
nography and the hyperplastic pattern in patients with renal 
hyperparathyroidism. Ther Apher Dial. 2008;12(5):391-395. 
27. Fraser WD. Hyperparathyroidism. Lancet. 2009;374(9684): 
145-158. 
28. Elder GJ. Parathyroidectomy in the calcimimetic era. Ne-
phrology (Carlton). 2005;10(5):511-515. 
29. Jeanguillaume C, Ureña P, Hindié E, et al. Secondary hy-
perparathyroidism: detection with I-123-Tc-99m-Sestamibi 
subtraction scintigraphy versus US. Radiology. 1998;207(1): 
207-213.
30. Mariani G, Gulec SA, Rubello D, et al. Preoperative local-
ization and radioguided parathyroid surgery. J Nucl Med. 
2003;44(9):1443-1458.
31. Kidney Disease: Improving Global Outcomes (KDIGO) CKD-
MBD Work Group. KDIGO clinical practice guideline for the 
diagnosis, evaluation, prevention, and treatment of Chronic 
Kidney Disease-Mineral and Bone Disorder (CKD-MBD). Kid-
ney Int Suppl. 2009;(113):S1-S130. 
32. Schömig M, Ritz E. Management of disturbed calcium me-
tabolism in uraemic patients: 2. Indications for parathyroid-
ectomy. Nephrol Dial Transplant. 2000;15 Suppl 5:25-29. 
33. Tominaga Y, Matsuoka S, Sato T. Surgical indications and 
procedures of parathyroidectomy in patients with chronic 
kidney disease. Ther Apher Dial. 2005;9(1):44-47. 
34. Fukagawa M, Kitaoka M, Tominaga Y, Akizawa T, Kuro-
kawa K. Selective percutaneous ethanol injection therapy 
(PEIT) of the parathyroid in chronic dialysis patients: the 
Japanese strategy. Nephrol Dial Transplant. 1999;14(11): 
2574-2577. 
35. Mauz PS, Stiegler M, Holderried M, Brosch S. Complications 
of ultrasound guided percutaneous ethanol injection thera-
py of the thyroid and parathyroid glands. Ultraschall Med. 
2005;26(2):142-145. 
8 © 2012 Società Italiana di Nefrologia - ISSN 1121-8428  
Meola et al: Ultrasound in secondary hyperparathyroidism
36. Koiwa F, Kakuta T, Tanaka R, Yumita S. Efficacy of percu-
taneous ethanol injection therapy (PEIT) is related to the 
number of parathyroid glands in haemodialysis patients with 
secondary hyperparathyroidism. Nephrol Dial Transplant. 
2007;22(2):522-528. 
37. Shiizaki K, Negi S, Mizobuchi M, et al. Effect of percutaneous 
calcitriol injection therapy on secondary hyperparathyroidism 
in uraemic patients. Nephrol Dial Transplant. 2003;18(90003)
(Suppl 3):iii42-iii46. 
38. de Barros Gueiros JE, Chammas MC, Gerhard R, et al. Per-
cutaneous ethanol (PEIT) and calcitrol (PCIT) injection therapy 
are ineffective in treating severe secondary hyperparathyroid-
ism. Nephrol Dial Transplant. 2004;19(3):657-663. 
39. Komaba H, Nakanishi S, Fujimori A, et al. Cinacalcet effec-
tively reduces parathyroid hormone secretion and gland vol-
ume regardless of pretreatment gland size in patients with 
secondary hyperparathyroidism. Clin J Am Soc Nephrol. 
2010;5(12):2305-2314. 
40. Kakuta T, Tanaka R, Kanai G, et al. Can cinacalcet replace 
parathyroid intervention in severe secondary hyperparathy-
roidism? Ther Apher Dial. 2009;13(Suppl 1):S20-S27. 
41. Meola M, Petrucci I, Colombini E, Barsotti G. Use of ul-
trasound to assess the response to therapy for second-
ary hyperparathyroidism. Am J Kidney Dis. 2011;58(3): 
485-491. 
42. Mendoza FJ, Lopez I, Canalejo R, et al. Direct upregulation of 
parathyroid calcium-sensing receptor and vitamin D receptor 
by calcimimetics in uremic rats. Am J Physiol Renal Physiol. 
2009;296(3):F605-F613. 
43. Mizobuchi M, Ogata H, Hatamura I, et al. Activation of 
calcium-sensing receptor accelerates apoptosis in hyper-
plastic parathyroid cells. Biochem Biophys Res Commun. 
2007;362(1):11-16. 
44. Lomonte C, Vernaglione L, Chimienti D, et al. Does vitamin 
D receptor and calcium receptor activation therapy play a 
role in the histopathologic alterations of parathyroid glands 
in refractory uremic hyperparathyroidism? Clin J Am Soc 
Nephrol. 2008;3(3):794-799.
Accepted: August 01, 2012
